Results 11 to 20 of about 2,224,846 (160)

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

Cells, 2021
Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs).
Nadiia Lypova, Susan M. Dougherty, Lilibeth Lanceta, Jason Chesney, Yoannis Imbert-Fernandez   +4 more
doaj   +2 more sources

Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines

Biomedicines, 2023
Resistance to protein tyrosine kinase inhibitors (TKIs) presents a significant challenge in therapeutic target development for cancers such as triple-negative breast cancer (TNBC), where conventional therapies are ineffective at combatting systemic ...
Cory Lefebvre, Sierra Pellizzari, Vasudeva Bhat, Kristina Jurcic, David W. Litchfield, Alison L. Allan   +5 more
doaj   +2 more sources

Molecular Mechanism of Erlotinib Resistance in Epidermal Growth Factor Receptor 
Mutant Non-small cell Lung Cancer Cell Line H1650

Chinese Journal of Lung Cancer, 2012
Background and objective Epidermal growth factor receptor (EGFR) overexpression and mutations were existed in more than 40% of the lung cancer, and it’s the one of molecular targets in clinical treatment.
Ruili HAN, Xiaoli WANG, Diansheng ZHONG, Juan ZHAO, Zhe CHEN, Linlin SUN, Jing WANG, Jinbang ZHANG   +7 more
doaj   +2 more sources

Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells [PDF]

Cell Death Discovery
Almost all non-small cell lung cancer (NSCLC) patients initially responding to EGFR tyrosine kinase inhibitors (TKIs) develop acquired resistance. Since KCa3.1 channels, expressed in mitochondria and plasma membrane, regulate similar behavioral traits of
Luca Matteo Todesca, Matthias Gerke, Emma Etmar Bulk, Magdalena Bachmann, Alisa Rudersdorf, Lorenzo Antonuzzo, Serena Pillozzi, Martina Düfer, Ildiko Szabo, Albrecht Schwab   +9 more
doaj   +2 more sources

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. [PDF]

Cancers (Basel), 2022
Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), but resistance inevitably develops as the disease progresses.
Jiang S, Huang J, He H, Liu Y, Liang L, Sun X, Li Y, Cong L, Qing B, Jiang Y.   +9 more
europepmc   +2 more sources

The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer [PDF]

Apoptosis: an International Journal on Programmed Cell Death, 2022
Jianmin Wang, Zhengtang Chen, Yongxin Yu
exaly   +2 more sources

DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer [PDF]

Cancers, 2020
György Marko-Varga, Balázs Döme, Ho Jeong Kwon   +2 more
exaly   +2 more sources

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Genome‐scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib‐resistant lung cancer

Molecular Oncology, 2021
Erlotinib is highly effective in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. However, despite initial favorable responses, most patients rapidly develop resistance to erlotinib soon after the initial treatment. This study
Jieun Lee, Ahyoung Choi, Sung‐Yup Cho, Yukyung Jun, Deukchae Na, Ahra Lee, Giyong Jang, Jee Young Kwon, Jaesang Kim, Sanghyuk Lee, Charles Lee   +10 more
doaj   +1 more source

Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2)

Cells, 2023
Oral squamous cell carcinoma (OSCC) frequently carries high epidermal growth factor receptor (EGFR) expression. Erlotinib, a small molecule tyrosine kinase inhibitor (TKI), is an effective inhibitor of EGFR activity; however, resistance to this drug can ...
Chien-Yi Chan, Shih-Cing Hong, Chin-Ming Chang, Yuan-Hong Chen, Pin-Chen Liao, Chun-Yin Huang   +5 more
doaj   +1 more source